Trinity Biotech plc (NASDAQ:TRIB – Get Rating) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 181,200 shares, a drop of 23.2% from the March 15th total of 235,800 shares. Based on an average trading volume of 125,200 shares, the short-interest ratio is currently 1.4 days.
TRIB stock opened at $1.22 on Monday. Trinity Biotech has a 12-month low of $0.86 and a 12-month high of $4.01. The stock has a market cap of $25.50 million, a price-to-earnings ratio of 13.56 and a beta of 1.55. The business’s 50-day moving average is $1.07 and its 200 day moving average is $1.49.
Trinity Biotech (NASDAQ:TRIB – Get Rating) last posted its quarterly earnings data on Monday, April 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.13). Trinity Biotech had a negative return on equity of 3,160.63% and a negative net margin of 7.42%.
A number of hedge funds have recently bought and sold shares of the stock. Hunter Associates Investment Management LLC boosted its holdings in Trinity Biotech by 9.1% in the 4th quarter. Hunter Associates Investment Management LLC now owns 2,286,150 shares of the company’s stock worth $3,269,000 after buying an additional 190,250 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in Trinity Biotech in the 4th quarter worth approximately $159,000. LPL Financial LLC lifted its stake in Trinity Biotech by 20.1% in the 4th quarter. LPL Financial LLC now owns 106,973 shares of the company’s stock worth $153,000 after purchasing an additional 17,900 shares in the last quarter. Millennium Management LLC purchased a new position in Trinity Biotech in the 3rd quarter worth approximately $139,000. Finally, Whitefort Capital Management LP purchased a new position in Trinity Biotech in the 4th quarter worth approximately $50,000. Institutional investors own 27.83% of the company’s stock.
Trinity Biotech Company Profile (Get Rating)
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.
- Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.